Form 4: United Therapeutics' President and COO, Michael Benkowitz, Executes Stock Options and Sells Shares Under 10b5-1 Plan

Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of common stock held in trusts, according to a Form 4 filing with the SEC.

Summary

• On February 18, 2025, Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of the company's common stock.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan established on August 7, 2024.
• The sales were conducted at various prices, with weighted average prices reported for each transaction.
• Some shares were held in a trust where Benkowitz and his spouse are co-trustees, while others were held in a trust for family members where Benkowitz has sole investment and voting power.
• Benkowitz exercised options to acquire 7,500 shares at $111 and sold 7,500 shares at $366.19, 600 shares at $368.3241, 1,432 shares at $369.653, 1,068 shares at $370.7036, 2,351 shares at $371.4666, 1,549 shares at $372.6252, and 400 shares at $373.6725.
• Benkowitz also exercised options to acquire 2,500 shares at $111 and sold 200 shares at $367.97, 500 shares at $369.426, 601 shares at $370.8541, 600 shares at $371.6717, 499 shares at $372.8185, and 100 shares at $374.18.
• Following these transactions, Benkowitz continues to indirectly hold shares through trusts.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock transactions under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment about the company's future.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects. Rule 10b5-1 plans are frequently used to schedule these transactions in advance, reducing the risk of insider trading allegations.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
• The use of Rule 10b5-1 trading plans is a standard practice among corporate executives to manage their stock holdings and avoid potential conflicts of interest.
• Comparable companies in the biotechnology sector, such as Amgen (AMGN) and Gilead Sciences (GILD), also see regular Form 4 filings related to executive stock transactions.

Stakeholder Impact

• The stock sales may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates